Optain

Name: Optain
Brand: Optain

Optain is a combined medical device, software, and clinical services platform for retinal screening that captures non-mydriatic retinal images, returns clinical reports via teleophthalmology or AI (outside the US), and integrates results into EHRs and quality dashboards.

Est 2019|Raised $37M

LinkedIn 932|Web traffic 2K|FTEs 20

01Competitive Landscape

Narrative analysis

Optain vs autonomous AI (EyeArt / LumineticsCore): - Optain’s US proposition is aligned with teleophthalmology grading rather than autonomous on-device AI. For clinics that require instant, in-visit autonomous diagnosis without remote graders, autonomous competitors may better match that requirement. - Conversely, buyers that prefer specialist over-reads, multi-condition grading, and ICD-10-coded reporting flowing into the EHR may favor a teleophthalmology model such as Optain with its integrated reading network. Optain vs IRIS (teleretinal screening): - IRIS operates a teleretinal screening and reading center model. Published evaluations of similar models suggest variable algorithm performance historically, which is why many programs emphasize reading center confirmation. - Optain’s acquisition of a reading network could enable rapid scaling of reading capacity and clinic relationships, depending on integration and operational execution. Optain vs camera-centric approaches (RetinaVue + reading services): - Camera-first solutions can offer procurement flexibility and potentially lower upfront costs; they allow buyers to select separate reading services. - Public reseller signals indicate some retinal cameras are available with explicit list prices; Optain does not publish device pricing, so ROI comparisons require vendor quotes.

	Optain	Eyenuk EyeArt	Digital Diagnostics LumineticsCore
Starting Price	Not publicly listed	Not publicly listed	Not publicly listed
Best For	Primary care / health systems seeking an integrated screening workflow with teleophthalmology reads (where autonomous AI is not the chosen pathway)	Sites seeking autonomous AI DR screening without human grading (vendor-stated rapid-result capability)	Sites seeking an autonomous, point-of-care DR diagnostic product with published validation history
Key Strength	Workflow-focused capture with teleophthalmology reporting and an integrated reading network enabled by a recent acquisition	Vendor-stated rapid autonomous reporting and FDA clearance history for certain configurations	Established product lineage and clinical validation from earlier autonomous DR products
Key Weakness	Public materials indicate automated detection is not sold in the US and the camera is not available for sale in the US (creates procurement ambiguity); limited public security disclosures	Camera compatibility constraints and scope that may focus on DR-specific use cases	May require specific camera workflows and clinic operational changes; pricing not transparent

01Competitive Landscape

Narrative analysis

Optain vs autonomous AI (EyeArt / LumineticsCore):

Optain’s US proposition is aligned with teleophthalmology grading rather than autonomous on-device AI. For clinics that require instant, in-visit autonomous diagnosis without remote graders, autonomous competitors may better match that requirement.
Conversely, buyers that prefer specialist over-reads, multi-condition grading, and ICD-10-coded reporting flowing into the EHR may favor a teleophthalmology model such as Optain with its integrated reading network.

Optain vs IRIS (teleretinal screening):

IRIS operates a teleretinal screening and reading center model. Published evaluations of similar models suggest variable algorithm performance historically, which is why many programs emphasize reading center confirmation.
Optain’s acquisition of a reading network could enable rapid scaling of reading capacity and clinic relationships, depending on integration and operational execution.

Optain vs camera-centric approaches (RetinaVue + reading services):

Camera-first solutions can offer procurement flexibility and potentially lower upfront costs; they allow buyers to select separate reading services.
Public reseller signals indicate some retinal cameras are available with explicit list prices; Optain does not publish device pricing, so ROI comparisons require vendor quotes.

	Optain	Eyenuk EyeArt	Digital Diagnostics LumineticsCore
Starting Price	Not publicly listed	Not publicly listed	Not publicly listed
Best For	Primary care / health systems seeking an integrated screening workflow with teleophthalmology reads (where autonomous AI is not the chosen pathway)	Sites seeking autonomous AI DR screening without human grading (vendor-stated rapid-result capability)	Sites seeking an autonomous, point-of-care DR diagnostic product with published validation history
Key Strength	Workflow-focused capture with teleophthalmology reporting and an integrated reading network enabled by a recent acquisition	Vendor-stated rapid autonomous reporting and FDA clearance history for certain configurations	Established product lineage and clinical validation from earlier autonomous DR products
Key Weakness	Public materials indicate automated detection is not sold in the US and the camera is not available for sale in the US (creates procurement ambiguity); limited public security disclosures	Camera compatibility constraints and scope that may focus on DR-specific use cases	May require specific camera workflows and clinic operational changes; pricing not transparent

Optain

01Competitive Landscape

Narrative analysis

02Market Map

01Competitive Landscape

Narrative analysis

02Market Map